Synthesis of CJ-15,208, a novel κ-opioid receptor antagonist
dc.contributor.author | Ross, Nicolette C. | |
dc.contributor.author | Kulkarni, Santosh S. | |
dc.contributor.author | McLaughlin, Jay P. | |
dc.contributor.author | Aldrich, Jane V. | |
dc.date.accessioned | 2017-04-19T20:37:01Z | |
dc.date.available | 2017-04-19T20:37:01Z | |
dc.date.issued | 2010-09-20 | |
dc.identifier.citation | Ross, Nicolette C. et al. “Synthesis of CJ-15,208, a Novel Κ-Opioid Receptor Antagonist.” Tetrahedron letters 51.38 (2010): 5020–5023. | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23743 | |
dc.description.abstract | The tryptophan isomers of the cyclic tetrapeptide CJ-15,208, reported to be a kappa opioid receptor (KOR) antagonist [Saito, T.; Hirai, H.; Kim, Y. J.; Kojima, Y.; Matsunaga, Y.; Nishida, H.; Sakakibara, T.; Suga, O.; Sujaku, T.; Kojima, N. J. Antibiot. (Tokyo) 2002, 55, 847–854.], were synthesized to determine the tryptophan stereochemistry in the natural product. A strategy was developed to select linear precursor peptides that favor cyclization using molecular modeling, and optimized cyclization conditions are reported. The optical rotation of the l-Trp isomer is consistent with that of the natural product. Unexpectedly both isomers exhibit similar nanomolar affinity for KOR. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 3.0 (CC BY-NC-ND 3.0 US), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ | |
dc.subject | Cyclic tetrapeptide | en_US |
dc.subject | Cyclization | en_US |
dc.subject | Molecular modeling | en_US |
dc.title | Synthesis of CJ-15,208, a novel κ-opioid receptor antagonist | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Aldrich, Jane V. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.1016/j.tetlet.2010.07.086 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License 3.0 (CC BY-NC-ND 3.0 US), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.